Pharmaceutical Executive February 19, 2024
Mike Hollan

Lightburn discusses his company’s work with psychedelics and the unique business strategies required for these treatments.

The life sciences industry is starting to embrace the idea that psychedelics can be useful therapies for certain conditions. Due to the illegal nature of the substances they’re derived from, however, working with these drugs can be uniquely difficult. Ben Lightburn, CEO of Filament Health, spoke with Pharmaceutical Executive about the successes and struggles of pharmaceutical psychedelics.

Pharmaceutical Executive: Can you discuss some of your recent successes?
Ben Lightburn: We developed specific technology that has allowed us to create the first and only pharmaceutical grade natural psychedelic drug candidates. We’re taking this natural approach for several...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Interview / Q&A, Mental Health, Pharma / Biotech, Provider, Trends
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds
STAT+: Nobel laureates call on National Academies and biotech CEOs to speak out against Trump attacks on science
Healthcare supply chain, pharmacy costs to rise in 2025: report
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA

Share This Article